Multiomics at Illumina: Sequencing Beyond the Genome

Illumina’s mission to unlock the power of the human genome has led to the development of genome sequencers that have transformed clinical diagnostics and biomedical research. Illumina is building on that vision by extending the use of their sequencing instruments beyond traditional genomics with a portfolio of multiomics products spanning epigenetics, transcriptomics, and proteomics. These end-to-end multiomics products will enable researchers and clinicians to integrate diverse biological data streams, offering unprecedented insights into disease mechanisms and paving the way for more precise diagnostics and targeted therapeutic strategies.